Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyAzCH Dronedarone Prior Auth Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.1024

    Dronedarone (Multaq)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.1024 alerts

    Get alerted when Policy AZ.CP.PMN.1024 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage criteria for dronedarone (Multaq) for Arizona Medicaid members enrolled with Arizona Complete Health, including AzCH-CCP and Care1st.

    Policy Summary
    PayerArizona Complete Health
    PolicyDronedarone (Multaq)
    Policy CodePolicy AZ.CP.PMN.1024
    Change TypeAdministrative and applicability clarification
    Effective DateMar 16, 2020
    Last ReviewFeb 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that the member meets all applicable approval criteria for Multaq.
    SourceLink
    POLICY UPDATE CHANGES

    The revision log records addition of the Care1st logo and language specifying that the criteria also apply to Care1st.

    12 monthsInitial and standard continued approval
    800 mg/dayMaximum covered daily dose
    400 mgTablet strength
    AF in sinus rhythmFDA-approved coverage population
    10

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Contraindications or boxed warnings

    Medical Necessity and Coverage Criteria

    Initial approval: atrial fibrillation

    Covered for initial approval when all atrial-fibrillation criteria are met.

    All required criteria

    • Clinical eligibility

      • Diagnosis and specialist management

        • The member has a diagnosis or history of atrial fibrillation (AF).
        • Multaq is prescribed by, or in consultation with, a cardiologist.
      • Treatment intent

        • Treatment is for maintenance of sinus rhythm.
        • The patient is planned to undergo cardioversion to sinus rhythm.
      • Heart-failure exclusions absent

        • The patient does not have NYHA Class IV heart failure.
        • The patient does not have symptomatic heart failure with recent decompensation requiring hospitalization.
      • The dose does not exceed 800 mg (2 tablets of 400 mg) per day.800 mg/day maximum

    Initial approval: other diagnoses

    Other diagnoses or indications may be considered under the applicable off-label policy.

    Other diagnoses: initial approval

    • If the diagnosis is not specifically listed under the policy’s non-authorized indications, refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid.

      Coverage remains subject to the applicable off-label use policy.

    Continued therapy: covered indications

    Continued therapy for indications in Section I requires all criteria below.

    All required criteria

    • The member is currently receiving the medication through the Centene benefit, or the member previously met initial approval criteria.
    • The member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed 800 mg (2 tablets of 400 mg) per day.800 mg/day maximum

    Continued therapy: other diagnoses

    Continued therapy for other diagnoses or indications must meet one of the listed pathways.

    ONE of the following pathways

    • Existing therapy

      • The member is currently receiving the medication through the Centene benefit.
      • Documentation supports a positive response to therapy.
    • Off-label review

      • If the diagnosis is not specifically listed under the policy’s non-authorized indications, refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid.

        Coverage remains subject to the applicable off-label use policy.

    Non-FDA-approved indications that are not addressed in this policy are excluded from coverage unless sufficient documentation of efficacy and safety supports review under the applicable off-label use policy, AZ.CP.PMN.53, for Arizona Medicaid.

    Coverage is excluded, and use may be clinically inappropriate, in contraindicated or boxed-warning situations, including decompensated heart failure or permanent atrial fibrillation, which carry an increased risk of death, stroke, and heart failure. Other restrictions include second- or third-degree AV block or sick sinus syndrome without a functioning pacemaker; bradycardia below 50 bpm; concomitant strong CYP3A inhibitor use; concomitant QT-prolonging drugs or herbal products that may induce Torsade de Pointes; severe hepatic impairment; hypersensitivity to dronedarone or its excipients; prior amiodarone-related liver or lung toxicity; pregnancy or nursing; and a QTc Bazett interval ≥500 msec.

    Coverage is not medically necessary for non-FDA-approved indications that are not addressed by this policy and do not meet the applicable off-label efficacy and safety documentation requirements under AZ.CP.PMN.53 for Arizona Medicaid.

    Dose and Clinical Limits

    Maximum daily dose
    Maximum covered dose≤800 mg/day
    Tablet equivalent2 tablets of 400 mg
    Bradycardia contraindication
    Bradycardia threshold<50 bpm
    QTc contraindication
    QTc Bazett interval threshold≥500 msec

    Prior Authorization and Request Requirements

    Prior Authorization

    Prior Authorization Documentation Required

    Provider must submit documentation demonstrating that the member meets all applicable approval criteria before Multaq (dronedarone) can be authorized.

    Documentation Required

    Clinical Supporting Documentation

    Acceptable supporting documentation may include office chart notes, laboratory results, and other relevant clinical information supporting the requested therapy and applicable criteria.

    • Office chart notes
    • Laboratory results
    • Other clinical information supporting medical necessity
    Documentation Required

    Clinical Background

    Dronedarone (Multaq) is an antiarrhythmic medication indicated to reduce the risk of hospitalization for atrial fibrillation in patients who are in sinus rhythm and have a history of paroxysmal or persistent atrial fibrillation. This policy addresses use for maintenance of sinus rhythm or planned cardioversion to sinus rhythm, subject to heart-failure exclusions, contraindications, other safety restrictions, and a maximum dose of 800 mg/day.

    Abbreviations

    Abbreviation
    FDAFood and Drug Administration
    Abbreviation
    AFAtrial fibrillation
    Abbreviation
    AFLAtrial flutter
    Policy Summary
    PayerArizona Complete Health
    PolicyDronedarone (Multaq)
    Policy CodePolicy AZ.CP.PMN.1024
    Change TypeAdministrative and applicability clarification
    Effective DateMar 16, 2020
    Last ReviewFeb 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that the member meets all applicable approval criteria for Multaq.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaDose and Clinical LimitsPrior Authorization and Request RequirementsClinical BackgroundAbbreviations

    Initial Request Details

    For an initial request for atrial fibrillation, submit documentation establishing the diagnosis and treatment plan, including the following requirements:

    • History of atrial fibrillation (AF).
    • Prescription by, or consultation with, a cardiologist.
    • Treatment for maintenance of sinus rhythm or a plan to undergo cardioversion to sinus rhythm.
    • No NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization.
    • Requested dose does not exceed 800 mg per day (two 400-mg tablets).
    Documentation Required

    Continuation Request Details

    For a continuation request, document ongoing eligibility and response to therapy. Requests may be approved for 12 months when the applicable continuation criteria are met.

    • Member is currently receiving the medication through a Centene benefit, or previously met the initial approval criteria.
    • Member is responding positively to therapy.
    • For a dose increase, the new dose does not exceed 800 mg per day (two 400-mg tablets).
    • For other diagnoses or indications, documentation must support a positive response when the member is currently receiving the medication through a Centene benefit; otherwise, refer to the applicable off-label use policy for the relevant line of business if the diagnosis is not specifically listed under Section III.
    • For other diagnoses or indications, the approval duration is the duration of the request or 12 months, whichever is less.
    Denial Risk

    Initial Criteria Not Met

    An initial atrial-fibrillation request is at risk for denial when required clinical or prescribing criteria are not met.

    • No documented history of atrial fibrillation.
    • The medication is not prescribed by, or in consultation with, a cardiologist.
    • The treatment is not intended to maintain sinus rhythm and the patient is not planned to undergo cardioversion to sinus rhythm.
    • The patient has NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization.
    • The requested dose exceeds 800 mg per day (two 400-mg tablets).
    Denial Risk

    Unapproved Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation of efficacy and safety is provided in accordance with the applicable off-label use policy.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53 when applicable.
    Denial Risk

    Contraindication or Boxed Warning

    Multaq may be denied or clinically inappropriate when a contraindication or boxed-warning condition applies, including the following:

    • Decompensated heart failure or permanent atrial fibrillation, due to the boxed warning regarding increased risk of death, stroke, and heart failure.
    • Second- or third-degree atrioventricular (AV) block or sick sinus syndrome, except with a functioning pacemaker.
    • Bradycardia below 50 beats per minute.
    • Concomitant use of a strong CYP3A inhibitor.
    • Concomitant use of QT-prolonging drugs or herbal products that may induce Torsade de Pointes.
    • Severe hepatic impairment.
    • Hypersensitivity to dronedarone or any of its excipients.
    • Liver or lung toxicity due to previous amiodarone use.
    • Pregnancy or nursing.
    • QTc Bazett interval of 500 msec or greater.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request is at risk for denial when the member does not meet the applicable ongoing-therapy, prior-approval, response, indication, or dosing requirements.

    • The member is not currently receiving the medication through a Centene benefit and has not previously met the initial approval criteria.
    • Documentation does not show a positive response to therapy.
    • A requested dose increase would exceed 800 mg per day (two 400-mg tablets).
    • For another diagnosis or indication, the request lacks documentation of positive response, does not satisfy the applicable off-label use policy, or concerns an indication not addressed for coverage under this policy.